Nutrition, food, supplements, exercise, sleep, stress, and lifestyle research for Crohn's disease and IBD.
Page 17 of 24 · 1124 articles
This study identifies a plant-derived compound (poricoic acid A) that reduced inflammation, cellular senescence, and colon injury in cell and mouse models of ulcerative colitis and links those effects to AMPK/PPARγ...
The study nominates specific compounds and molecular targets from a traditional herbal formulation that could be investigated as potential anti-inflammatory agents for ulcerative colitis, helping bridge chemical...
Older adults with IBD are at higher risk of functional decline; SE and PT are low-risk interventions that may help reduce frailty, sarcopenia, fatigue, joint pain, and improve postoperative recovery and quality of life.
Disability related to IBD affects daily functioning and quality of life; identifying factors linked with higher or lower disability (vitamin D status, azathioprine use, smoking) can help patients and clinicians consider...
The paper reports a material that preserved barrier proteins and reduced inflammatory signaling in cell and mouse models of ulcerative colitis; this could point to a low-cost adjunct approach for protecting the colonic...
Crohn's can affect more than the gut; a coordinated multidisciplinary team helps manage intestinal disease plus common extraintestinal issues (nutrition, skin, joints, eyes, mental health). Knowing which specialists to...
This research links a bacterial surface capsule to how well a gut microbe colonizes the intestine and to lower inflammatory responses in mouse models, which may help explain strain differences seen in Crohn’s disease and...
Dietary strategies are commonly considered by people with IBD to manage symptoms and quality of life. This trial focuses on real-world adherence and patient-reported barriers to three popular diets (intermittent fasting,...
If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.
New analytical tools for longitudinal microbiome data can reveal time-varying microbial signatures tied to Crohn's disease and ulcerative colitis. Identifying such biomarkers may eventually inform diagnosis, monitoring,...
Low zinc levels were linked with higher one-year relapse risk in UC patients in remission; knowing zinc status might add prognostic information beyond standard labs.
Lung involvement is an underrecognized extraintestinal complication in IBD and can reflect disease activity, altered gut–lung immune signaling, or medication toxicity — distinguishing the cause is important for...
The study describes a novel hydrogel designed to deliver sinapic acid directly to the inflamed colon and release drug in response to a reducing environment—an approach that could improve targeted oral therapies for...
The study links paternal exposure to an emerging PFAS chemical (OBS) with epigenetic changes in sperm that may increase offspring susceptibility to colitis, highlighting a possible environmental pathway relevant to IBD...
The study identifies a plant extract that reduced inflammation and oxidative stress and altered molecular pathways (Nrf2/Keap1, NF-κB) and lncRNA expression in a rat colitis model—potential leads for future IBD research...
The work suggests a microbe–metabolite–immune pathway (B. pseudolongum → taurine metabolites → M2 macrophages) that could point to future microbiome- or metabolite-targeted therapies for ulcerative colitis, which may be...
The study suggests a herbal formula (H7F) may protect intestinal barrier function, modulate the gut microbiome, and suppress IL-17/NF-κB inflammation in a mouse colitis model—mechanisms relevant to IBD pathophysiology.
This study suggests a specific gut microbe might reduce gut inflammation in a mouse colitis model and may boost the benefit of infliximab, which could point toward microbiota‑based adjuncts to current IBD therapies.
People with IBD (including children) often have damaged gut barriers and altered microbiomes that can worsen inflammation and metabolic health. Dietary and nutritional approaches discussed here may help reduce...
Researchers are exploring plant polyphenols and new oral delivery systems that might reduce gut inflammation and modify microbiota — findings in mice suggest potential but are not directly applicable to patients yet.
Patients and clinicians managing ulcerative colitis in India may have greater access to an effective oral treatment (tofacitinib) that can reduce steroid dependence and is available as lower-cost generics. This could...
Fear of movement was substantially more common and often more severe in people with Crohn’s disease in this study, which could act as a barrier to exercise and rehabilitation. Addressing kinesiophobia may help improve...
If biologic availability, infusion capacity, or therapeutic drug monitoring are limited where you live, oral JAK inhibitors could offer a practical, effective alternative for moderate‑to‑severe IBD, according to this...
The study suggests a new experimental compound (7-KC delivered in mβCD) reduced colitis severity in an acute mouse model, which could inform early-stage therapeutic research targeting immune cell membrane properties.
The trial tests a palatable elemental diet (mBIOTA) as a non-drug approach for treating outpatient IBD flares, which could reduce reliance on steroids and other medications if shown effective and tolerable.
Depressive symptoms are common in IBD and can worsen quality of life and disease management; non-drug options that may improve mood are especially relevant for patients seeking adjunctive or accessible therapies.
This study suggests that boosting Nrf2 activity in CD4+ T cells can reduce inflammatory Th1/Th17 responses and increase regulatory T cells, which may help control colonic inflammation in ulcerative colitis.
The study suggests chronic gut inflammation can cause measurable brain inflammation and neuronal dysfunction in an IBD model, and that creatine supplementation prevented those changes — a potential neuromodulatory...
This research suggests a common environmental contaminant (6PPD-quinone from tire rubber) can disrupt lipid metabolism and mitochondrial function in human colon cells and increase inflammatory signals linked to IBD.
People with IBD may be interested because the review identifies polysaccharides from traditional Chinese medicine as a potential source of new therapies that act on gut microbes, the intestinal barrier, and immune...
The study points to a new local mechanism—ferroportin in colon macrophages—that links iron handling, the microbiome, and mucosal healing. If validated, this could lead to targeted treatments that help healing without...
Low-FODMAP diets are commonly used to reduce GI symptoms in IBS and sometimes in UC.
The study identifies a probiotic species (B. pseudolongum) and its acetate production as potential ways to limit a genotoxic E. coli and reduce inflammation in a mouse model — suggesting a microbiome-based avenue that...
Vitamin D deficiency is common in people with IBD and may relate to disease activity, complications, and quality of life; understanding this link could influence monitoring and adjunctive care.
The work links a missing bacterial metabolite (HDCA) to macrophage metabolism and reduced intestinal inflammation in experimental models, highlighting a potential microbiome-derived pathway that could be targeted for...
This study identifies plant extracts—especially Commiphora gileadensis—that reduced inflammation and tissue injury in cell assays and an acute rat model of ulcerative colitis, suggesting new leads for future IBD drug...
TRPV channels are proposed as integrative mediators of inflammation, angiogenesis, and oxidative stress in IBD, suggesting new mechanistic targets that could eventually yield novel therapies for Crohn's disease and...
The study identifies a natural compound that reduced inflammation and improved multiple aspects of intestinal barrier function in a zebrafish IBD model, suggesting a new candidate for preclinical drug discovery relevant...
The report suggests a probiotic (VSL#3TM) added to vedolizumab may speed or increase early response in ulcerative colitis, which could interest patients and clinicians seeking ways to improve biologic induction outcomes....
The study suggests that combining different fermentable fibers may steer the gut microbiome toward more butyrate-producing bacteria and away from pro-inflammatory lineages—changes that could be relevant to IBD-related...
People with UC on or starting vedolizumab may be interested because the study tests whether adding an oral CurQD supplement improves remission rates compared with vedolizumab alone. The trial could inform whether this...
The record concerns a planned surgical approach using a patient's own bone marrow–derived stem cells to try to heal fistulating perianal Crohn's disease—an often hard-to-treat complication that substantially affects...
Environmental pollutants that are increasing in many East Asian settings — air pollution, heavy metals, pesticides, and microplastics — may contribute to rising IBD rates by affecting the gut microbiome and intestinal...
The study identifies a candidate compound (NCTD) that reduced inflammation and tissue damage in a rat ulcerative colitis model and implicates specific inflammatory, epigenetic, metabolic, and antioxidant pathways —...
The study identifies specific anti-inflammatory compounds in Artemisia scoparia and shows they reduce inflammation in cell and mouse models of ulcerative colitis, suggesting potential new leads for drug or...
The paper highlights how the gut microbiome and environment can strongly influence colitis severity in genetically susceptible mice, illustrating a gene–environment–microbiome axis that may help explain heterogeneity in...
The study identifies a potential new mechanism—blocking ferroptosis via CA9—for reducing intestinal inflammation in a mouse model, which could guide future IBD drug research.
Higher, optimised doses of prolonged-release mesalazine were linked with fewer clinical recurrences over 12 months in adults with mild-to-moderate UC, which could influence treatment decisions about mesalazine dose and...
